Anastrozole can be used for the treatment of advanced breast cancer in postmenopausal women, as well as for the adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women, or for the adjuvant treatment of hormone receptor-positive early-stage breast cancer in postmenopausal women who have received 2-3 years of adjuvant tamoxifen therapy. It is mainly used after surgery and chemotherapy to consolidate the therapeutic effect and to prevent the recurrence of breast cancer. Anastrozole is a third-generation specific aromatase inhibitor, which works by lowering the level of estradiol in the blood and does not affect the synthesis of cortisol and aldosterone, and it can inhibit the aromatization link in the process of converting androgens secreted by adrenal glands into estrogens, thus lowering the level of estradiol. Specific dosage patients should be taken under the guidance of a clinician, if there are any symptoms of discomfort must be promptly go to the hospital.